These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 4008930)

  • 1. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
    Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
    J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective.
    Livingston PO; DeLeo AB; Jones M; Oettgen HF
    J Immunol; 1983 Nov; 131(5):2601-5. PubMed ID: 6631013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
    Livingston PO; Calves MJ; Natoli EJ
    J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.
    O'Boyle KP; Zamore R; Adluri S; Cohen A; Kemeny N; Welt S; Lloyd KO; Oettgen HF; Old LJ; Livingston PO
    Cancer Res; 1992 Oct; 52(20):5663-7. PubMed ID: 1394190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas.
    Coggin JH
    Mol Biother; 1989; 1(4):223-8. PubMed ID: 2818874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas.
    Palladino MA; Srivastava PK; Oettgen HF; DeLeo AB
    Cancer Res; 1987 Oct; 47(19):5074-9. PubMed ID: 3497717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients.
    Russell PS; Chase CM; Burton RC
    J Immunol; 1983 Feb; 130(2):951-7. PubMed ID: 6336775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of levamisole on methylcholanthrene-induced tumor. I. Its antitumor effect and immunological mechanism].
    Gomi K; Morimoto M; Nomoto K
    Gan To Kagaku Ryoho; 1982 Jul; 9(7):1262-8. PubMed ID: 7184454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
    Borden EC; Sidky YA; Hatcher JF; Bryan GT
    Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological analysis of cell surface antigens on methylcholanthrene-induced mouse sarcomas with antisera produced against the tumors.
    Tanimoto M; Takahashi T; Nishizuka Y
    Gan; 1982 Apr; 73(2):184-92. PubMed ID: 6288499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fractional cyclophosphamide dosage on sheep red blood cell-delayed-type hypersensitivity response in mice.
    Rondinone SN; Giovanniello OA; Barrios HA; Nota NR
    J Immunol; 1983 Apr; 130(4):1600-3. PubMed ID: 6220061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
    Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting passive monoclonal antibody therapy of Moloney sarcoma in BALB/c mice.
    Kennel SJ; Lankford PK; Flynn KM; Winegar R
    Cancer Res; 1985 Aug; 45(8):3782-9. PubMed ID: 2410101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular immunity to solubilized tumor antigens of a methylcholanthrene-induced sarcoma with a migration inhibition assay.
    Padarathsingh ML; Dean JH; McCoy JL; Lewis DD; Northing JW; Natori T; Law LW
    J Immunol; 1978 Jun; 120(6):1981-5. PubMed ID: 659888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
    Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
    Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of levamisole on methylcholanthrene-induced tumor. II. Potentiation of cytotoxic T-cell activities].
    Gomi K; Morimoto M; Nomoto K
    Gan To Kagaku Ryoho; 1982 Jul; 9(7):1269-76. PubMed ID: 6985196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of a M(r) 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma.
    De Leo AB; Becker M; Lu L; Law LW
    Cancer Res; 1993 Apr; 53(7):1602-7. PubMed ID: 7680955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s).
    Lamon EW; Skurzak HM; Andersson B; Whitten HD; Klein E
    J Immunol; 1975 Apr; 114(4):1171-6. PubMed ID: 1117138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.